Elevance Health (ELV) Soars as Investors Gain Confidence in Profitability

Elevance Health, Inc. (NYSE:ELV), formerly known as Anthem, experienced a surge in stock price during Q2 2026, as highlighted in First Eagle Global Fund's Q2 2026 investor letter. The company's shares closed at $392.54 per share on August 31, 2026, reflecting a 21.78% increase over the past year. Despite concerns about fiscal constraints and limited policy flexibility, strong demand for financial assets, led by AI infrastructure developments, contributed to a positive market environment.

The fund's performance was primarily driven by emerging markets and developed Europe, with information technology and financials leading among equity sectors. Elevance Health, Inc. (NYSE:ELV) saw a 3.85% gain over the past month, with its shares trading within a 52-week range of $274.84 to $436.24. The fund underperformed relative to the MSCI World Index during the quarter, but Elevance Health, Inc. (NYSE:ELV) still emerged as a notable contributor.